Cargando…
Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells
Signal transducer and activator of transcription 3 (STAT3) has been shown to play a critical role in the maintenance of cancer stem cells (CSCs). Hence, the inhibition of STAT3 signaling has been suggested to be a viable therapeutic approach for cancers. Moreover, the efficacy of combinations of che...
Autores principales: | Chung, Shin-Yi, Chen, Yen-Hsi, Lin, Pei-Rong, Chao, Ta-Chung, Su, Jung-Chen, Shiau, Chung-Wai, Su, Yeu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089896/ https://www.ncbi.nlm.nih.gov/pubmed/30109144 http://dx.doi.org/10.1038/s41420-018-0084-z |
Ejemplares similares
-
Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis
por: Su, Tung-Hung, et al.
Publicado: (2017) -
SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014) -
SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014) -
Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017) -
Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
por: Su, Jung-Chen, et al.
Publicado: (2018)